Conversation with The Cancer Letter Trump’s plans for Inova reach across the Washington Beltway, through Virginia—and beyond November 10, 2017Vol.43 No.42By Paul Goldberg
Conversation with The Cancer Letter Peter Pisters reflects on the upcoming challenge: leading MD Anderson November 03, 2017Vol.43 No.41By Paul Goldberg
Conversation with The Cancer Letter Storniolo: The Komen Tissue Bank fills the gap in understanding of “normal” October 27, 2017Vol.43 No.40By Matthew Bin Han Ong
Conversation with The Cancer Letter Rosenberg: Yescarta is going to be lifesaving for patients with lymphomas October 20, 2017Vol.43 No.39By Matthew Bin Han Ong
Conversation with The Cancer Letter UPMC’s Ferris: “Now there are more system-wide pressures to make a budget and to monitor quality” October 20, 2017Vol.43 No.39By Paul Goldberg
Conversation with The Cancer Letter Rubin: FDA helped Merck figure out how to channel science into regulatory approval October 13, 2017Vol.43 No.38By Paul Goldberg
Conversation with The Cancer Letter Lemery: “We saw consistent evidence of the drug’s response in multiple tumor types” October 13, 2017Vol.43 No.38By Paul Goldberg
Conversation with The Cancer LetterFree Allan Erickson: “I think Philip Morris has a long-term goal of a smoke-free world October 06, 2017Vol.43 No.37By Paul Goldberg
Conversation with The Cancer LetterFree Matt Myers: Philip Morris has a long history of funding what it calls independent research by previously credible researchers October 06, 2017Vol.43 No.37By Paul Goldberg
Conversation with The Cancer Letter Ashworth’s challenge: Build one very big data sharing system across the University of California cancer centers September 15, 2017Vol.43 No.34By Matthew Bin Han Ong
